- Home
- OGI vs DRTS Comparison
OGI vs DRTS Comparison
Compare OGI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- DRTS
- Stock Information
- Founded
- OGI 2013
- DRTS 2015
- Country
- OGI Canada
- DRTS Israel
- Employees
- OGI N/A
- DRTS N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- OGI Health Care
- DRTS Health Care
- Exchange
- OGI Nasdaq
- DRTS Nasdaq
- Market Cap
- OGI 169.4M
- DRTS 155.9M
- IPO Year
- OGI N/A
- DRTS N/A
- Fundamental
- Price
- OGI $1.44
- DRTS $2.23
- Analyst Decision
- OGI
- DRTS Strong Buy
- Analyst Count
- OGI 0
- DRTS 3
- Target Price
- OGI N/A
- DRTS $8.00
- AVG Volume (30 Days)
- OGI 651.8K
- DRTS 23.0K
- Earning Date
- OGI 12-17-2024
- DRTS 11-29-2024
- Dividend Yield
- OGI N/A
- DRTS N/A
- EPS Growth
- OGI N/A
- DRTS N/A
- EPS
- OGI N/A
- DRTS N/A
- Revenue
- OGI $110,297,722.00
- DRTS N/A
- Revenue This Year
- OGI $8.76
- DRTS N/A
- Revenue Next Year
- OGI $14.04
- DRTS N/A
- P/E Ratio
- OGI N/A
- DRTS N/A
- Revenue Growth
- OGI 2.33
- DRTS N/A
- 52 Week Low
- OGI $1.19
- DRTS $1.75
- 52 Week High
- OGI $2.91
- DRTS $3.40
- Technical
- Relative Strength Index (RSI)
- OGI 30.47
- DRTS 47.79
- Support Level
- OGI $1.52
- DRTS $2.14
- Resistance Level
- OGI $1.64
- DRTS $2.30
- Average True Range (ATR)
- OGI 0.10
- DRTS 0.08
- MACD
- OGI -0.03
- DRTS -0.00
- Stochastic Oscillator
- OGI 0.00
- DRTS 45.00
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.